Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ORCL +33.3%, GME +11.1%, MEI +9.5%, AVAV +3.3%, TSM +2.5% (Aug revs), IMOS +0.9% (Aug revs)
Other news:
- ASST +128.3% (shareholders approve merger with Strive)
- GLSI +29.5% (FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population)
- TVTX +21.9% (provides update on FDA Advisory Committee meeting for FILSPARI)
- KPTI +16.6% (Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis)
- FFAI +10.5% (Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status)
- BILL +5.7% (FT story on Elliot Management building stake)
- EQ +3.3% (stock offering by selling shareholders)
- TLX +3.2% (Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis)
- HRTX +2.3% (stock offering by selling shareholders, relates to purchase agreement; also $125 mln mixed shelf offering)
- WALD +2.2% (FDA approval of Obagi saypha MagIQ injectable hyaluronic acid gel under the Obagi Medical Brand)
- PLTR +2% (announced a partnership which will see Hadean's leading edge wargaming, command & control and battlefield training products deployed on Palantir's Foundry software)
- RNA +1.5% (Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44)
- NVO +1.2% (launches major transformation to streamline operations and reinforce growth)
- HUM +1.1% (receives court approval for bid to acquire assets of The Villages Health)
- BKD +1% (reports August occupancy)